

NCTN Adolescent and Young Adult (AYA) Cancer Trials Portfolio (Updated on 4/15/2026)

Click on trial number to go to the associated ClinicalTrials.gov webpage, to view the protocol title and the study information.

Newly Diagnosed Disease

Osteosarcoma (Pulmonary mets)

[AOST2031](#)

Osteosarcoma (High Grade)

[AOST2032](#)

Classical Hodgkin Lymphoma

[AHOD2131](#)

Invasive Breast Carcinoma (HR+/HER2-)

[NRG-BR009 \(OFSET\)*^](#)

Germ Cell Tumors

[AGCT1531](#)

[AGCT1532](#)

Precursor B-Lymphoblastic Leukemia (B-Cell ALL)

[A041501*](#)

Adrenocortical Carcinoma

[A092204](#)

Low-grade Astrocytoma

[A072301](#)

Recurrent Disease

Precursor B-Lymphoblastic Leukemia (B-Cell ALL)

[AALL1821](#)

Osteosarcoma (Pulmonary mets)

[AOST2031](#)

Precursor T-Lymphoblastic Leukemia/ Lymphoma (T-Cell ALL/LBL) - MRD

[EA9213](#)

Adrenocortical Carcinoma

[A092204](#)

Legend by Disease Types

Green = Osteosarcoma

Orange = Hodgkin Lymphoma

Purple = Breast

Yellow = Germ Cell Tumors

Blue = B-Cell ALL

Light Green = Adrenocortical Carcinoma

Light Gray = Low-grade Astrocytoma

Light Blue = T-Cell ALL / T-Cell LBL

Note: * NRG-BR009 and A041501: Age 18 years and older; ^ NRG-BR009: COG is not directly participating.

NCTN Adolescent and Young Adult (AYA) Cancer Trials (Open as of 4/15/2026)

Protocol Number	Phase	Protocol Title
A041501	III	A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL
A072301	III	Phase III Trial of Radiotherapy Followed by Adjuvant Temozolomide in Combination with the IDH Inhibitor Vorasidenib vs Placebo in IDH-Mutated Newly-Diagnosed Grade 3 Astrocytomas
A092204	II	A Phase II Study of Cabozantinib in Combination with Cemiplimab (REGN2810) (Cabo-Cemiplimab (REGN-2810)) Versus Cabozantinib Alone in Adolescents and Adults with Advanced Adrenocortical Cancer
AALL1821	II	A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged ≥ 1 to < 31 Years Old with First Relapse
AGCT1531	III	A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
AGCT1532	III	A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Germ Cell Tumors
AHOD2131	III	A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
AOST2031	III	A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma
AOST2032	II/III	A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
EA9213	II	A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL)
NRG-BR009	III	A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤ 25 (OFSET)